Pipeline

Our lead drug candidate, saroglitazar, is a liver-selective, dual PPAR alpha / gamma agonist. Saroglitazar is an investigational treatment which has received Fast Track designation and orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of patients with primary biliary cholangitis (PBC). Saroglitazar is also in development as an investigational treatment for the treatment of 
non-alcoholic steatohepatitis (NASH).